Specialty Pharmacy

Disabled Medicare beneficiaries, especially those with many comorbidities, continue to struggle to afford prescriptions.

Significant correlation found between physicians who accept industry money from pharmaceutical or medical device companies and brand name prescribing rates.

Physicians who accept industry money from pharmaceutical or medical device companies more likely to prescribe high rates of brand name drugs.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Genetic and molecular specialized testing may improve targeted therapy for skin cancer.

Cellular protein helps HIV remain undetected.

Signs of multiple sclerosis may be found via magnetic resonance imaging scanners in the near future.

New generation of oncology drugs could improve treatment for patients with therapy-resistant cancer.

Top stories of the week on Specialty Pharmacy Times.

Recent advances and updates in oncology and cancer drug development.

The targeted multi-kinase inhibitor sorafenib is the standard of care for advanced HCC, but it has limited therapeutic benefit.

Aberrant protein mutation associated with the black plague may lead to treatments for HIV and hepatitis C.

Special interest legislation could inflate generic drug prices.

Subset of T cells can confer therapeutic immune responses.

Nanoparticles can change shape to gain entry into diseased tissue and reduce the toxic effects of chemotherapy.

Twitter can increase awareness and patient recruitment for clinical trials of cancer drugs.

Using PBM tools at current levels can save payers $654 billion over the next 10 years.

The high cost of HCV treatment remains a hurdle for patients, payers, and providers.

Nonmedical workers and mobile technology can play a pivotal role in risk prediction.

Histologic improvement greater with experimental drug versus placebo in patients with moderate-to-severe ulcerative colitis.

Individual genetic backdrop may be less important than previously thought in the development of multiple sclerosis.

Promising study may lead to targeted treatment for patients with ALL.

Zidovudine can decrease HIV transmission by 70% in non-breastfed babies.

Pluripotent stem cells may lead to potential cure for hemophilia A.

Women are more likely to contract HIV from infected men.

Out-of-pocket costs can lead to the reduced use of preventive services and increased use of preventive medications.

Researchers seek to develop drugs that are less toxic and achieve longer remissions in multiple myeloma patients.

Efficacy of Truvada varies by gender in HIV treatment.